{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:40:04Z","timestamp":1756323604221,"version":"3.44.0"},"reference-count":9,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,9,5]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Inhibitors of BRAF, a gene coding a protein called B-raf, with or without inhibitors of MEK (MAPK\/extracellular signal-regulated kinase) are often used as palliative treatment in BRAF-mutated metastatic melanoma. Recent data show improved progression-free survival with encorafenib with binimetinib, a newer BRAF\/MEK inhibitor combination, compared with older agents, but there have been no reports of this treatment in the setting of renal and liver failure. We report a patient with disease-induced transaminitis and renal failure requiring dialysis who was successfully treated with encorafenib and binimetinib. His transaminitis improved and he was able to stop dialysis without any significant adverse effects during treatment, suggesting encorafenib with binimetinib may be used safely and effectively even in patients with end organ damage.<\/jats:p>","DOI":"10.1136\/bcr-2019-230974","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T21:06:31Z","timestamp":1568667991000},"page":"e230974","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment"],"prefix":"10.1136","volume":"12","author":[{"given":"P","family":"Ngo","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, University of Louisville School of Medicine, Louisville, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Bycroft","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Louisville, Louisville, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"2025082712121237000_12.9.e230974.1","unstructured":"Institute, N. C. Cancer Stat Factors: Melanoma of the Skin. 2019. Retrieved from https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"2025082712121237000_12.9.e230974.2","unstructured":"Array BioPharma Inc. Mektovi (binimetinib) [prescribing information. Boulder, CO: Array BioPharma Inc, 2019."},{"key":"2025082712121237000_12.9.e230974.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"2025082712121237000_12.9.e230974.4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2017.04.007","article-title":"Open-label, multicentre safety study of vemurafenib in\u00a03219 patients with BRAF\n                  V600\n                mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis","volume":"79","author":"Blank","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025082712121237000_12.9.e230974.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"2025082712121237000_12.9.e230974.6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082712121237000_12.9.e230974.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"2025082712121237000_12.9.e230974.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2923"},{"key":"2025082712121237000_12.9.e230974.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-230974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:12:18Z","timestamp":1756321938000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-230974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,16]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bcr-2019-230974"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-230974","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}